New Diabetes Drugs & Dialysis Impact Immune Cell Traps in Kidney Disease
Background
Diabetes Mellitus and various Kidney Diseases are often characterized by chronic inflammation, a key contributor to disease progression. A significant factor in this inflammation is NETosis, the formation of Neutrophil Extracellular Traps (NETs) by neutrophils, which can exacerbate tissue damage. Current knowledge lacks a clear understanding of how specific anti-glycemic medications and immunosuppressive therapies influence NETosis in these patient populations.
Study Design
Results
This recruiting study (NCT06821919) aims to quantify how SGLT2 inhibitors (Forxiga/Jardiance) and GLP-1 agonists (Ozempic) impact NETosis levels in diabetic patients. Researchers will measure specific biomarkers of NETosis from serum samples collected at multiple time points over 12 months. The study also seeks to characterize NETosis in various immune-mediated kidney diseases and after immunosuppressive therapy, comparing these to healthy controls to establish baseline differences. The central hypothesis is that these anti-glycemic therapies will significantly reduce NETosis, thereby mitigating inflammation and kidney injury in diabetic patients.
Why It Matters
Reducing NETosis could represent a novel therapeutic strategy for managing inflammation and progression in diabetic kidney disease and immune-mediated kidney diseases. Identifying specific drug classes like SGLT2 inhibitors or GLP-1 agonists that modulate NETosis could lead to improved patient outcomes and inform new treatment guidelines. This observational clinical study could provide crucial mechanistic insights, paving the way for future Phase II or III clinical trials focused on kidney protection and anti-inflammatory effects.